一线化疗对不同血红蛋白水平患者临床疗效研究.docVIP

一线化疗对不同血红蛋白水平患者的临床疗效研究 　　[摘要] 目的 本研究通?^将数种实体瘤患者分为血红蛋白水平≥100 g/L的实体瘤化疗方案组、血红蛋白水平90～100 g/L的实体瘤化疗方案组及血红蛋白水平90 g/L的实体瘤化疗方案组的化疗疗效进行临床对比分析，以获取血红蛋白水平对化疗疗效影响的更多临床直接依据。 方法 选择我院从2015年5月～2016年11月住院的Ⅲ、Ⅳ期实体瘤患者180例进行回顾性分析，患者依据化疗前和化疗后的血红蛋白浓度平均值将类型、期别、治疗方案相同的肿瘤分为A组（血红蛋白水平≥100 g/L）、B组（血红蛋白水平90～100 g/L）、C组（血红蛋白水平90 g/L）。对三个方案组化疗疗效进行对比及评价。 结果 经过治疗，A组的客观有效率为55.00%，B组的客观有效率为36.67%，C组的客观有效率为20.00%，三组的客观有效率相对比差异具有统计学意义（P0.05）。 结论 改善贫血在提高化疗疗效中起到积极作用，改善化疗疗效最终能延长患者生存期及改善其生活质量。 　　[关键词] 肿瘤；化疗；血红蛋白；贫血；实体瘤 　　[中图分类号] R730.5 [文献标识码] B [文章编号] 1673-9701（2017）12-0098-03 　　[Abstract] Objective To clinical compare and analyze the efficacy of chemotherapy by assigning patients with several types of solid tumors into solid tumor chemotherapy regimen group with hemoglobin level ≥100 g/L， solid tumor chemotherapy regimen group with hemoglobin level of 90-100 g/L and solid tumor chemotherapy regimen group with hemoglobin level of 90 g/L， so as to obtain more direct clinical basis of the effect of hemoglobin levels on the efficacy of chemotherapy. Methods 180 patients with stage Ⅲ and Ⅳ solid tumors were retrospectively reviewed in our hospital from May 2015 to November 2016. The patients with the tumors of the same time， stage and treatment regimen were divided into group A （hemoglobin level ≥100 g/L）， group B（hemoglobin level 90-100 g/L）， group C （hemoglobin level 90 g/L） according to the average level of hemoglobin before and after the chemotherapy. The efficacy of chemotherapy in the three groups was compared and evaluated. Results After treatment， the objective effective rate in group A was 55.00%， the objective effective rate in group B was 36.67%， and the objective effective rate in group C was 20.00%. The differences in objective effective rates among the three groups were statistically significant（P0.05）. Conclusion Improving anemia can play a positive role in improving the efficacy of chemotherapy， which can prolong patients survival time and improve their quality of life. 　　[Key words] Tumo